Impact Biomedical Inc. (NYSEAMERICAN: IBO) shares rose 86.28% in after-hours trading to $0.77 on Wednesday following a Securities and Exchange Commission filing disclosing amendments to its pending merger with Cayman Islands-based global pharmaceutical company Dr Ashleys Bio Labs Limited.
According to Benzinga Pro data, IBO closed regular trading up 0.80% at $0.41.
Revised Share Allocation, DSS Obligations Updated
On Feb. 27, Impact Biomedical amended its Merger and Share Exchange Agreement, originally dated Jun. 21, 2025, extending the end date from Mar. 31 to Jul. 1, 2026.
Under amended terms, Dr Ashleys Limited will issue 169.5 million ordinary shares to its sole shareholder at closing, representing 94.20% of the company’s total issued and outstanding shares, excluding CEO compensation shares and shares to be …
